Form 4: Anteris Technologies CFO Matthew McDonnell Reports Stock Option and Unit Awards
SEC Form 4 Filing
Anteris Technologies CFO Matthew McDonnell reported the acquisition of stock options, share price performance units, and restricted stock units on December 16, 2024.
Summary
- Matthew McDonnell, the Chief Financial Officer of Anteris Technologies Global Corp., reported several transactions related to stock options and units.
- On December 16, 2024, McDonnell acquired stock options with exercise prices of $4.33, $5.65, and $8.25, totaling 112,001 options.
- He also acquired 233,334 share price performance units and 83,333 restricted stock units.
- The stock options and share price performance units were originally issued by Anteris Technologies Ltd and assumed by Anteris Technologies Global Corp.
- The options vest over three years, while the share price performance units vest over two years, and the restricted stock units vest over three years.
- Some of the options are held indirectly through the McDonnell Family Trust.
Sentiment
Score: 7
Explanation: The document is a routine filing of stock option and unit grants to a company executive. It is a positive sign that the CFO is incentivized to perform well, but it is not a major event that would significantly impact the company's valuation.
Positives
- The grant of stock options and units to the CFO aligns his interests with the company's performance.
- The vesting schedules for the options and units encourage long-term commitment from the CFO.
- The share price performance units incentivize the CFO to drive stock price appreciation.
Risks
- The value of the stock options and units is dependent on the future performance of Anteris Technologies' stock price.
- The vesting of the options and units is contingent on the CFO's continued service with the company.
Future Outlook
The vesting of the options and units is subject to the CFO's continued service with the company and the performance of the stock price.
Industry Context
This filing is a standard SEC Form 4, which is required when company insiders make transactions in their company's stock. It is common for executives to receive stock options and units as part of their compensation package.
Comparison to Industry Standards
- Stock option and unit grants are a common form of executive compensation in the biotechnology and medical device industries.
- Companies like Medtronic, Boston Scientific, and Abbott also use stock options and restricted stock units to incentivize their executives.
- The vesting schedules and performance-based units are also standard practices in the industry to align executive interests with shareholder value.
Stakeholder Impact
- Shareholders may view the stock option and unit grants as a positive sign that the CFO is incentivized to increase shareholder value.
- Employees may see the grants as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 12/16/2024 | Date of the reported transactions, including the acquisition of stock options, share price performance units, and restricted stock units. |
| 07/12/2020 | Start date for vesting of the first tranche of the $4.33 stock options. |
| 09/23/2022 | Start date for vesting of the first tranche of the $5.65 stock options. |
| 09/19/2023 | Start date for vesting of the first tranche of the $8.25 stock options. |
| 09/13/2025 | Start date for vesting of the first tranche of the share price performance units. |
| 12/16/2025 | Start date for vesting of the first tranche of the restricted stock units. |
| 07/12/2029 | Expiration date of the $4.33 stock options. |
| 09/23/2026 | Expiration date of the $5.65 stock options. |
| 06/13/2027 | Expiration date of the $8.25 stock options. |
Keywords
stock options, share price performance units, restricted stock units, insider trading, executive compensation, Anteris Technologies, Matthew McDonnell, AVR
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.